Condition: Hereditary Angioedema · HAE · Hereditary Angioedema - Type 1 · Sponsor: ADARx Pharmaceuticals, Inc.
This study will evaluate the efficacy and safety of ADX-324 in participants with Type 1 or Type 2 hereditary angioedema. The study will also evaluate safety, pharmacokinetics (PK), pharmacodynamics (PD), and health-related quality of life measures.
This description comes directly from the study's public registry record.
Lupe Gallegos · 877-232-7974 · info@adarx.com
Always discuss trial participation with your own doctor first.
| ADARx Clinical Site | Litchfield Park, Arizona, United States | Recruiting |
| ADARx Clinical Site | Little Rock, Arkansas, United States | Recruiting |
| ADARx Clinical Site | San Diego, California, United States | Recruiting |
| ADARx Clinical Site | Walnut Creek, California, United States | Recruiting |
| ADARx Clinical Site | Orlando, Florida, United States | Recruiting |
| ADARx Clinical Site | Chevy Chase, Maryland, United States | Recruiting |
| ADARx Clinical Site | Wheaton, Maryland, United States | Recruiting |
| ADARx Clinical Site | Detroit, Michigan, United States | Recruiting |
| ADARx Clinical Site | St Louis, Missouri, United States | Recruiting |
| ADARx Clinical Site | Las Vegas, Nevada, United States | Recruiting |
| ADARx Clinical Site | New York, New York, United States | Recruiting |
| ADARx Clinical Site | Cincinnati, Ohio, United States | Recruiting |
+ 39 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06960213